knowledge -WSS

knowledge

author：entertainment 2025-08-28 08:39:59 - browse：752

Peter Marks. -- health coverage from STAT — Peter Marks, Director of the Center for Biologics Evaluation and Research at the Food and Drug Administration. Susan Walsh-Pool/Getty Images

Peter Marks wants drug developers to ask more stupid questions.

It’s part of the top Food and Drug Administration official’s plan to reinvigorate gene therapy, a field that has struggled despite significant technological advances. Some companies are shelving programs or going out of business, even when they have promising data.

The problems are numerous: The diseases are often exceptionally rare, limiting the potential market. Manufacturing at commercial quality is complex and expensive. Proving a drug works can be difficult, because there may be too few patients to run a traditional randomized study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： 2024 GOP presidential candidates spar over abortion in debate

WSS

AstraZeneca bets AAV gene therapy will still deliver the goods

AstraZeneca bets AAV gene therapy will still deliver the goods

Why do we get seasonal allergies?

Psilocybin's anti

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

hotspot

knowledge

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

AstraZeneca challenges Medicare drug negotiation program

At least 13 dead in Texas as scorching temps continue

Diversity in medical illustrations gets boost from Chidiebere Ibe

Wildfire smoke exposes gaps in outdoor worker protections

Appeals court upholds limits to abortion pill

After affirmative action ruling, medical educators look to 'holistic review'

AstraZeneca bets AAV gene therapy will still deliver the goods

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Apellis safety probe of eye disease drug centers on injection needle

hotspot

Feds fine Medicare Advantage plans for overcharging members

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

GOP inquiry over gain

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Newly formed Hurricane Beatriz sweeps close to Mexico's southwest Pacific coast

How to make Best Hospitals ratings actually useful for patients

explore

focus

explore

entertainment